NeoRhea phase II study – secondary analysis on ctDNA monitoring
The NeoRhea study is a phase 2 clinical trial that focuses on patients with estrogen receptor-positive/HER2-negative early breast cancer. The treatment approach involves administering neoadjuvant palbociclib in combination with endocrine therapy for a duration of 4 months.
Dr Alexandra Stanciu, from the Institut Jules Bordet in Brussels, presented a poster at the ASCO conference highlighting the significance of circulating tumour DNA (ctDNA) monitoring within the study. The findings shed light on the value of ctDNA as a monitoring tool in assessing treatment response and guiding clinical decision-making in this patient population.
With the educational support of:
